Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robin L Jones

Showing results (311-320 of 393) with videos related to

Pageof 40
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 30, 2023
Clinical Benefit of Avapritinib in KIT-Mutant Gastrointestinal Stromal Tumors: A Post Hoc Analysis of the Phase I NAVIGATOR and Phase I/II CS3007-001 StudiesMichael C Heinrich, Xinhua Zhang, Robin L Jones, et al.
BMC Cancer|December 13, 2022
Patient-reported outcomes in individuals with advanced gastrointestinal stromal tumor treated with ripretinib in the fourth-line setting: analysis from the phase 3 INVICTUS trialPatrick Schöffski, Suzanne George, Michael C Heinrich, et al.
European Journal of Cancer (Oxford, England : 1990)|January 19, 2021
Avapritinib in unresectable or metastatic PDGFRA D842V-mutant gastrointestinal stromal tumours: Long-term efficacy and safety data from the NAVIGATOR phase I trialRobin L Jones, César Serrano, Margaret von Mehren, et al.
Annals of Surgical Oncology|September 19, 2019
Outcome of Primary Desmoid Tumors at All Anatomic Locations Initially Managed with Active SurveillanceWinan J van Houdt, Olga Husson, Alisha Patel, et al.
Cancers|March 10, 2022
Immunologic Gene Signature Analysis Correlates Myeloid Cells and M2 Macrophages with Time to Trabectedin Failure in Sarcoma PatientsBrett A Schroeder, Yuzheng Zhang, Kimberly S Smythe, et al.
Anticancer Research|March 27, 2026
Analysis of Clinical Benefit Using DNG64-<i>CAR-V</i> Chimeric Tumor Targeted Amphotropic RNA Vector in <i>CCNG1</i> Expressing CancersSant P Chawla, Samantha Jeffrey, Skyler S Pang, et al.
Cancer Medicine|April 29, 2023
Physical symptom burden in patients with desmoid-type fibromatosis and its impact on health-related quality of life and healthcare useAnne-Rose W Schut, Leanne E de Bruin, Belle H de Rooij, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 29, 2024
Clinical Implications and Molecular Features of Extracellular Matrix Networks in Soft Tissue SarcomasValeriya Pankova, Lukas Krasny, William Kerrison, et al.
Oral Diseases|March 16, 2026
Genomic Landscape of Myoepithelial Carcinoma TumorsMayukha Kashyap, Hollis Wright, JiHyeon Byun, et al.
Future Oncology (London, England)|February 11, 2025
SaLudo: a randomized phase IIb/III study of lurbinectedin plus doxorubicin as first-line treatment in leiomyosarcomaGregory M Cote, Sant P Chawla, George Demetri, et al.
Pageof 40

Showing results (311-320 of 393) with videos related to

Sort By:
Pageof 40
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 30, 2023
Clinical Benefit of Avapritinib in KIT-Mutant Gastrointestinal Stromal Tumors: A Post Hoc Analysis of the Phase I NAVIGATOR and Phase I/II CS3007-001 StudiesMichael C Heinrich, Xinhua Zhang, Robin L Jones, et al.
BMC Cancer|December 13, 2022
Patient-reported outcomes in individuals with advanced gastrointestinal stromal tumor treated with ripretinib in the fourth-line setting: analysis from the phase 3 INVICTUS trialPatrick Schöffski, Suzanne George, Michael C Heinrich, et al.
European Journal of Cancer (Oxford, England : 1990)|January 19, 2021
Avapritinib in unresectable or metastatic PDGFRA D842V-mutant gastrointestinal stromal tumours: Long-term efficacy and safety data from the NAVIGATOR phase I trialRobin L Jones, César Serrano, Margaret von Mehren, et al.
Annals of Surgical Oncology|September 19, 2019
Outcome of Primary Desmoid Tumors at All Anatomic Locations Initially Managed with Active SurveillanceWinan J van Houdt, Olga Husson, Alisha Patel, et al.
Cancers|March 10, 2022
Immunologic Gene Signature Analysis Correlates Myeloid Cells and M2 Macrophages with Time to Trabectedin Failure in Sarcoma PatientsBrett A Schroeder, Yuzheng Zhang, Kimberly S Smythe, et al.
Anticancer Research|March 27, 2026
Analysis of Clinical Benefit Using DNG64-<i>CAR-V</i> Chimeric Tumor Targeted Amphotropic RNA Vector in <i>CCNG1</i> Expressing CancersSant P Chawla, Samantha Jeffrey, Skyler S Pang, et al.
Cancer Medicine|April 29, 2023
Physical symptom burden in patients with desmoid-type fibromatosis and its impact on health-related quality of life and healthcare useAnne-Rose W Schut, Leanne E de Bruin, Belle H de Rooij, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 29, 2024
Clinical Implications and Molecular Features of Extracellular Matrix Networks in Soft Tissue SarcomasValeriya Pankova, Lukas Krasny, William Kerrison, et al.
Oral Diseases|March 16, 2026
Genomic Landscape of Myoepithelial Carcinoma TumorsMayukha Kashyap, Hollis Wright, JiHyeon Byun, et al.
Future Oncology (London, England)|February 11, 2025
SaLudo: a randomized phase IIb/III study of lurbinectedin plus doxorubicin as first-line treatment in leiomyosarcomaGregory M Cote, Sant P Chawla, George Demetri, et al.
Pageof 40